DOI:
10.1055/s-00034925
Hämostaseologie
LinksClose Window
References
Bacon CL, Singleton E, Brady B. , et al.
Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
Haemophilia 2011;
17 (03) 407-411
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.